ArticleBMC cancer2004
Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia.
Article in BMC cancer, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 85 citations in OpenAlex.
- Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial.Leukemia research · 2021Trial
- A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103).Breast cancer research and treatment · 2012Trial
- Trial
- Epigenome-wide association of neonatal methylation and trimester-specific prenatal PMEnvironmental epidemiology (Philadelphia, Pa.) · 2022Article
- Development and validation of an RNA-seq-based transcriptomic risk score for asthma.Scientific reports · 2022Article
- Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma.Oncogene · 2022Article
- Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells.Blood advances · 2021Article
- Multiple Transcriptome Data Analysis Reveals Biologically Relevant Atopic Dermatitis Signature Genes and Pathways.PloS one · 2015Article
- Combined p21-activated kinase and farnesyltransferase inhibitor treatment exhibits enhanced anti-proliferative activity on melanoma, colon and lung cancer cell lines.Molecular cancer · 2013Article
- Network of brain protein level changes in glutaminase deficient fetal mice.Journal of proteomics · 2013Article
- Validation of MIMGO: a method to identify differentially expressed GO terms in a microarray dataset.BMC research notes · 2012Article
- Targeting of CD34+CD38- cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in Acute Myeloid Leukaemia.BMC cancer · 2012Article
- The clinically relevant pharmacogenomic changes in acute myelogenous leukemia.Pharmacogenomics · 2012Review
- Tipifarnib-mediated suppression of T-bet-dependent signaling pathways.Cancer immunology, immunotherapy : CII · 2012Article
- Opposing effects of monomeric and pentameric C-reactive protein on endothelial progenitor cells.Basic research in cardiology · 2011Article
- Inter-chromosomal variation in the pattern of human population genetic structure.Human genomics · 2011Article
- Article
- Driven to death: Inhibition of farnesylation increases Ras activity and promotes growth arrest and cell death [corrected].Molecular cancer therapeutics · 2010Article
- Genomic and geographic distribution of private SNPs and pathways in human populations.Personalized medicine · 2009Article
- Applications of microarray technology to Acute Myelogenous Leukemia.Cancer informatics · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFarnesyl protein transferase inhibitors (FTIs) were originally developed to inhibit oncogenic ras, however it is now clear that there are several other potential targets for this drug class. The FTI tipifarnib (ZARNESTRA, R115777) has recently demonstrated clinical responses in adults with refractory and relapsed acute leukemias. This study was conducted to identify genetic markers and pathways that are regulated by tipifarnib in acute myeloid leukemia (AML).
methodsTipifarnib-mediated gene expression changes in 3 AML cell lines and bone marrow samples from two patients with AML were analyzed on a cDNA microarray containing approximately 7000 human genes. Pathways associated with these expression changes were identified using the Ingenuity Pathway Analysis tool.
resultsThe expression analysis identified a common set of genes that were regulated by tipifarnib in three leukemic cell lines and in leukemic blast cells isolated from two patients who had been treated with tipifarnib. Association of modulated genes with biological functional groups identified several pathways affected by tipifarnib including cell signaling, cytoskeletal organization, immunity, and apoptosis. Gene expression changes were verified in a subset of genes using real time RT-PCR. Additionally, regulation of apoptotic genes was found to correlate with increased Annexin V staining in the THP-1 cell line but not in the HL-60 cell line.
conclusionsThe genetic networks derived from these studies illuminate some of the biological pathways affected by FTI treatment while providing a proof of principle for identifying candidate genes that might be used as surrogate biomarkers of drug activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.